Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | What’s next for clinical trials in Alzheimer’s disease?

Jesse Cedarbaum, MD, FAAN, FANA, Yale University School of Medicine, New Haven, CT & Coeruleus Clinical Sciences LLC, Woodbridge, CT, shares his perspectives on recent advancements and future directions in Alzheimer’s disease (AD) research. Namely, Prof. Cedarbaum believes that emphasis should be placed on combination therapies, particularly those that utilize the body’s immune system such as the anti-PD-L1 antibody, IBC-Ab002. Recent advancements in the use of plasma biomarkers will reduce the cost of AD clinical trials by making it easier to pre-screen patients and track biomarker outcomes. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.